Publications by authors named "Harry Miao"

Claim this Profile
F
Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma.
Sattva S Neelapu, Julio C Chavez, Alison R Sehgal, Narendranath Epperla, Matthew L Ulrickson, Harry Miao

J Clin Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outpatient axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma: ZUMA-24 primary analysis.
Lori A Leslie, John H Baird, Ian W Flinn, Michael Tees, Daanish Hoda, Harry M Miao

Am J Cancer Res· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical, tumor, and product features associated with outcomes after axicabtagene ciloleucel therapy in follicular lymphoma.
Soumya Poddar, Jiali Yan, Gayatri Tiwari, Darawan Rinchai, Justin Budka, Harry Miao

J Clin Invest· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucel.
Frederick L Locke, Tanya Siddiqi, Caron A Jacobson, Sarah Nikiforow, Sairah Ahmed, Harry Miao

Blood Adv· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tocilizumab Prophylaxis Following Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma.
Frederick L Locke, Sattva S Neelapu, Nancy L Bartlett, Lazaros J Lekakis, Caron A Jacobson, Harry Miao

Transplant Cell Ther· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity.
Frederick L Locke, Tanya Siddiqi, Caron A Jacobson, Armin Ghobadi, Sairah Ahmed, Harry Miao

Blood· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapy.
Matthew A Lunning, Hai-Lin Wang, Zhen-Huan Hu, Frederick L Locke, Tanya Siddiqi, Harry Miao

Am J Hematol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brentuximab vedotin with chemotherapy in adolescents and young adults with stage III or IV classical Hodgkin lymphoma in ECHELON-1.
Howland E Crosswell, Ann S LaCasce, Nancy L Bartlett, David J Straus, Kerry J Savage, Harry Miao

Haematologica· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids.
Olalekan O Oluwole, Edouard Forcade, Javier Muñoz, Sophie de Guibert, Julie M Vose, Harry Miao

Bone Marrow Transplant· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors.
Dejan Juric, Minal Barve, Ulka Vaishampayan, Desamparados Roda, Aitana Calvo, Harry Miao

Cancer Med· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5).
Sattva S Neelapu, Julio C Chavez, Alison R Sehgal, Narendranath Epperla, Matthew Ulrickson, Harry Miao

Blood· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma.
Frederick L Locke, Simone Filosto, Justin Chou, Saran Vardhanabhuti, Regis Perbost, Harry Miao

Nat Med· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma.
Sattva S Neelapu, Caron A Jacobson, Armin Ghobadi, David B Miklos, Lazaros J Lekakis, Harry Miao

Blood· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I, first-in-human study of TAK-164, an antibody-drug conjugate, in patients with advanced gastrointestinal cancers expressing guanylyl cyclase C.
Richard Kim, Alexis D Leal, Aparna Parikh, David P Ryan, Shining Wang, Harry Miao

Cancer Chemother Pharmacol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: A phase I, first-in-human study of TAK-164, an antibody-drug conjugate, in patients with advanced gastrointestinal cancers expressing guanylyl cyclase C.
Richard Kim, Alexis D Leal, Aparna Parikh, David P Ryan, Shining Wang, Harry Miao

Cancer Chemother Pharmacol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia.
Keith W Pratz, Jason Kaplan, Moshe Levy, Dale Bixby, Patrick W Burke, Harry Miao

Haematologica· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659).
Leo I Gordon, Reem Karmali, Jason B Kaplan, Rakesh Popat, Howard A Burris, Harry Miao

Oncotarget· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2.
Kerry J Savage, Steven M Horwitz, Ranjana Advani, Jacob Haaber Christensen, Eva Domingo-Domenech, Harry Miao

Blood Adv· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II single-arm study of brentuximab vedotin in Chinese patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large cell lymphoma.
Yuqin Song, Ye Guo, Huiqiang Huang, Wei Li, Xiaoyan Ke, Harry Miao

Expert Rev Hematol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of front-line treatments for advanced Hodgkin lymphoma: a systematic literature review.
Mehul Dalal, Jatin Gupta, Kim Price, Athanasios Zomas, Harry Miao

Expert Rev Hematol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma.
Leo I Gordon, Jason B Kaplan, Rakesh Popat, Howard A Burris, Silvia Ferrari, Harry Miao

Clin Cancer Res· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study.
David J Straus, Monika Długosz-Danecka, Sergey Alekseev, Árpád Illés, Marco Picardi, Harry Miao

Blood· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Bayesian three-parameter logistic model for early- and late-onset DLTs in oncology Phase I studies.
Wei Zheng, Yang Zhao, Yuefeng Lu, Harry Miao, Hengchang Liu

J Biopharm Stat· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I trial of SAR103168, a novel multi-kinase inhibitor, in patients with refractory/relapsed acute leukemia or high-risk myelodysplastic syndrome.
Gail J Roboz, H Jean Khoury, Elias Jabbour, Wilena Session, Ellen K Ritchie, Harry Miao

Leuk Lymphoma· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2.
Jaishri O Blakeley, D Gareth Evans, John Adler, Derald Brackmann, Ruihong Chen, Harry Miao

Am J Med Genet A· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis